These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34670529)

  • 1. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.
    Lee JY; Oh K; Hong HS; Kim K; Hong SW; Park JH; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Lee HS; Jo KW; Park SH
    BMC Gastroenterol; 2021 Oct; 21(1):390. PubMed ID: 34670529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.
    Kang J; Jeong DH; Han M; Yang SK; Byeon JS; Ye BD; Park SH; Hwang SW; Shim TS; Jo KW
    J Korean Med Sci; 2018 Nov; 33(47):e292. PubMed ID: 30450023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
    Sousa M; Ladeira I; Ponte A; Fernandes C; Rodrigues A; Silva AP; Silva J; Gomes C; Afeto E; Carvalho J
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1099-1102. PubMed ID: 31206406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy.
    Çekiç C; Aslan F; Vatansever S; Topal F; Yüksel ES; Alper E; Dallı A; Ünsal B
    Ann Gastroenterol; 2015; 28(2):241-246. PubMed ID: 25831138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.
    Lee JW; Choi CH; Park JH; Kim JW; Kang SB; Koo JS; Kim YH; Kim YS; Joo YE; Chang SK
    Intest Res; 2016 Apr; 14(2):146-51. PubMed ID: 27175115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy.
    Kim J; Im JP; Yim JJ; Lee CK; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Korean J Gastroenterol; 2020 Jan; 75(1):29-38. PubMed ID: 31986571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018.
    Jung SM; Han M; Kim EH; Jung I; Park YB
    Arthritis Res Ther; 2022 Jun; 24(1):157. PubMed ID: 35761359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy.
    Shim TS
    Intest Res; 2014 Jan; 12(1):12-9. PubMed ID: 25349559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.